Revolution Medicines reports positive pancreatic cancer trial results

May 31, 2026 8:06 AM

Revolution Medicines Inc. (NASDAQ: RVMD) announced results from its Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found